Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Rep ; 23(2): 349-360, 2018 Apr 10.
Article in English | MEDLINE | ID: mdl-29641996

ABSTRACT

Transcriptional dysregulation of the MYC oncogene is among the most frequent events in aggressive tumor cells, and this is generally accomplished by acquisition of a super-enhancer somewhere within the 2.8 Mb TAD where MYC resides. We find that these diverse cancer-specific super-enhancers, differing in size and location, interact with the MYC gene through a common and conserved CTCF binding site located 2 kb upstream of the MYC promoter. Genetic perturbation of this enhancer-docking site in tumor cells reduces CTCF binding, super-enhancer interaction, MYC gene expression, and cell proliferation. CTCF binding is highly sensitive to DNA methylation, and this enhancer-docking site, which is hypomethylated in diverse cancers, can be inactivated through epigenetic editing with dCas9-DNMT. Similar enhancer-docking sites occur at other genes, including genes with prominent roles in multiple cancers, suggesting a mechanism by which tumor cell oncogenes can generally hijack enhancers. These results provide insights into mechanisms that allow a single target gene to be regulated by diverse enhancer elements in different cell types.


Subject(s)
Enhancer Elements, Genetic , Proto-Oncogene Proteins c-myc/metabolism , Amino Acid Motifs , Binding Sites , CCCTC-Binding Factor/metabolism , CRISPR-Cas Systems/genetics , Cell Line, Tumor , Cell Proliferation , DNA Methylation , Gene Editing , Gene Expression Regulation, Neoplastic , Humans , Promoter Regions, Genetic , Protein Binding , Proto-Oncogene Proteins c-myc/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...